Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive

@article{Han2014ExpertOO,
  title={Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive},
  author={Leo Han and J. Jensen},
  journal={Expert Opinion on Pharmacotherapy},
  year={2014},
  volume={15},
  pages={2071 - 2079}
}
Introduction: Oral contraceptives are often prescribed in extended or continuous forms in order to manage menstrual bleeding and menstrual-related side effects. However, with extended regimens, unscheduled intracycle bleeding can become problematic. Flexible extended dosing of a contraceptive containing drospirenone (DRSP) and ethinyl estradiol (EE) was designed to improve bleeding profiles during extended cycles through active management of bleeding symptoms. Areas covered: We examine the… Expand
View on Taylor & Francis
ncbi.nlm.nih.gov
5 Citations
Background Citations
3

5 Citations

Citation Type

Citation Type

Advances in pharmacotherapy for treating endometriosis
Treatment of pain associated with deep endometriosis: alternatives and evidence.
Sexuality and Disabil ity in Adolescents
Sexuality and Disability in Adolescents.
Regulation of Cervical Mucus Secretion

References

SHOWING 1-10 OF 49 REFERENCES
Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.
Contraceptive efficacy and tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study
Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results.
Long-term tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study
Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.
Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone.
A multicenter, randomized study of an extended cycle oral contraceptive.
Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone
Continuous Combination Oral Contraceptive Pills to Eliminate Withdrawal Bleeding: A Randomized Trial
Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study
...
1
2
3
4
5
...